Exagen Inc . (NASDAQ:XGN) reported Q2 EPS of ($0.78), $0.21 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $9 million versus the consensus estimate of $12.03 million.
GUIDANCE:
Exagen Inc. sees Q3 2022 revenue of $35-40 million, versus the consensus of $53.35 million.